The effects of whole-body exposure to ambient temperatures of −15°C and 23°C on selected performance-related physiological variables were investigated in elite nonasthmatic cross-country skiers. At an ambient temperature of −15°C we also studied the effects of the selective β₂-adrenergic agonist Salbutamol (0.4 mg × 3) which was administered 10 min before the exercise test. Eight male cross-country skiers with known maximal oxygen uptakes (V˙O_{2 max} ) of more than 70 ml · kg⁻¹ · min⁻¹ participated in the study. Oxygen uptake (V˙O₂), heart rate (f _c), blood lactate concentration ([La⁻]_b) and time to exhaustion were measured during controlled submaximal and maximal running on a treadmill in a climatic chamber. Lung function measured as forced expiratory volume in 1 s (FEV₁) was recorded immediately before the warm-up period and at the conclusion of the exercise protocol. Submaximal V˙O₂ and [La⁻]_b at the two highest submaximal exercise intensities were significantly higher at −15°C than at 23°C. Time to exhaustion was significantly shorter in the cold environment. However, no differences in V˙O_{2 max} or f _c were observed. Our results would suggest that exercise stress is higher at submaximal exercise intensities in a cold environment and support the contention that aerobic capacity is not altered by cold exposure. Furthermore, we found that after Salbutamol inhalation FEV₁ was significantly higher than after placebo administration. However, the inhaled β₂-agonist Salbutamol did not influence submaximal and maximal V˙O₂, f _c, [La⁻]_b or time to exhaustion in the elite, nonasthmatic cross-country skiers we studied. Thus, these results did not demonstrate any ergogenic effect of the β₂-agonist used.